TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06669117: FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Sponsor: Pierre Fabre Medicament · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,591,820

Rescue Site Savings

+$1,727,880

Unlock Full NCT06669117 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06669117 Rescue Dossier →